-transparent.png){kind=logo}
Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in follicular lymphoma grade 1), and substantial responses in T-cell lymphomas (1 of 4 in peripheral T-cell lymphoma and 2 of 7 in adult T-cell leukemia/lymphoma). Leukopenia was frequent but tolerable, and diarrhea minimal. Combination chemotherapy with a reduced dose CPT-11 and ADM was useful in the treatment of relapsed non-Hodgkin's lymphoma.
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
July 2001,
Oncology (Williston Park, N.Y.),
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
December 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
January 1989,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
March 2004,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
March 2011,
Expert review of anticancer therapy,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
April 2000,
Leukemia & lymphoma,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
January 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
July 2001,
Annals of hematology,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
March 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
T Saotome, and
T Takagi, and
C Sakai, and
K Kumagai, and
J Tamaru
July 1994,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
